Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer

NCT00415285 is registered in ClinicalTrials.gov with Georgia Center for Oncology Research & Education as lead sponsor.

NCT NCT00415285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00415285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer
Lead sponsor
Georgia Center for Oncology Research & Education
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2006
Completion date
Not reported
Enrollment
100
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms